Lyndsay Norine Harris MD

Breast Cancer, Clinical Informatics

Associate Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI

9609 Medical Center DriveBethesda, MD 20892
Phone+1 240-276-6327

Dr. Harris is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Harris' full profile Already have an account?

Summary

Lyndsay Harris, MD, is a medical oncologist working at the National Cancer Institute, NIH. She specializes in breast cancer, genomics, biomarkers and Precision Medicine such as the NCI-MATCH study. She completed her fellowship in medical oncology at University of British Columbia and her Breast Cancer Fellowship at Georgetown University Hospital after graduating from the University of Alberta. Dr. Harris has expertise in conditions such as hematologic oncology, breast cancer, drug development and myeloid disorders. Her research has been published in various journals including the Journal of Pathology Informatics and JAMA Oncology. She has contributed to clinical trials focused on precision medicine treatment based on genomic markers and has been recognized with several awards, such as America's Top Doctors by Castle Connolly in 2014 and multiple CMS Meaningful Use Stage 1 Certifications.

Education & Training

MedStart Georgetown University HospitalFellowship, Medical Oncology, 1991 - 1994
University of AlbertaClass of 1988

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 2012 - 2026
CT State Medical License 2006 - 2012

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts FollowMyHealth, Allscripts, 2015-2016
CMS Meaningful Use Stage 1 Certification Rhapsody Connect, Orion Health, 2015-2016
CMS Meaningful Use Stage 1 Certification Rhapsody Integration Engine, Orion Health, 2015-2016

Clinical Trials

Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
TERMINATED
PHASE1
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
TERMINATED
PHASE3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Start of enrollment: 2013 Dec 17
COMPLETED
PHASE3

Publications & Presentations

PubMed

ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.
Vivek Subbiah, Fengmin Zhao, Ragini R Kudchadkar, Ryan J Sullivan, Helen X Chen
Clinical Cancer Research. 2026-08-11
Associations of Age With Tumor Genomic Characteristics in Relapsed/Refractory Cancers Interrogated With the NCI-MATCH Trial Targeted Gene Panel Assay.
Hari Sankaran, Yuri Kotliarov, Yingdong Zhao, Lyndsay N Harris, James V Tricoli
JCO Precision Oncology. 2026-08-01
Perspectives From an Expert-Guided Discussion on Maximizing the Research Potential of Small Biopsy Tissue.
Lokesh Agrawal, P Mickey Williams, Helen M Moore, Kelly B Engel, Sarah R Greytak
JCO Precision Oncology. 2026-07-01

Journal Articles

Effect of Capivasertib in Patients with an AKT1 E17K-Mutated Tumor
Kevin Kalinsky, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology
The Challenge for Development of Valuable Immuno-Oncology Biomarkers
Arta M Monjazeb, Janice M Mehnert, Lyndsay N Harris, Clinical Cancer Research

Press Mentions

NCI-MATCH Cancer Trial Finds a Promising Signal for the AKT Inhibitor IpatasertibOctober 26th, 2022
ECOG-ACRIN Opens a New NCI-MATCH Treatment Arm for dMMR and LAG-3-Positive Cancers as It Continues to Locate Patients with BRAF MutationsMarch 16th, 2022
12 Open Arms in NCI-MATCH Treatment Trial Await Patients with Advanced or Rare CancersApril 26th, 2021

Grant Support

Targeted Combinations For Her2- Positive Breast Cancer BiologyNational Cancer Institute2008–2009
P-2: Target Combinations For HER2 - Positive Breast CancerNational Cancer Institute2005–2007
Core--Tissue And PathologyNational Cancer Institute2000–2002
Erbb2/P53 And Taxane Chemotherapy For Breast CancerNational Cancer Institute1999–2000